Worth reading
51Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.This transaction
This share acquisitionCounterpartyNot disclosed due to confidentiality obligations with the counterparty.
Disclosing companyNAKANISHI INC.
TimelineThe spacing between the points is proportional to the actual number of days.
Target company
脳神経外科用医療機器の製造および販売, 機械加工および成型された部品の製造
Location 989 Main Street Acton, MA 01720, USA, 979 Main Street Acton, MA 01720, USAShare capital 1 千米ドル（150 千円）, 21 千米ドル（3,150 千円）Date of incorporation 1982 年 7 月 16 日, 1966 年 4 月 19 日
Consideration and expenses
Acquisition price相手先である個人との守秘義務を有しており、Not disclosedとさせていただきます。
Impact on Business Performance
Acra Cut 社および Intech 社の新規連結に伴い、業績予想を上方修正
Procedures and assumptions
Valuation methodology第三者によるデューディリジェンス結果や当社による株式価値算定結果をふまえた合理性のある価額として決定
| Item | Details |
|---|---|
| Transaction name | This share acquisition |
| Counterparty name | Not disclosed due to confidentiality obligations with the counterparty. |
| Name of the Subject Company | Acra Cut, Inc., Intech, Inc. |
| Business Description of the Subject Company | 脳神経外科用医療機器の製造および販売, 機械加工および成型された部品の製造 |
| Location of the Subject Company | 989 Main Street Acton, MA 01720, USA, 979 Main Street Acton, MA 01720, USA |
| Capital Stock of the Subject Company | 1 千米ドル（150 千円）, 21 千米ドル（3,150 千円） |
| Date of Establishment of the Subject Company | 1982 年 7 月 16 日, 1966 年 4 月 19 日 |
| Acquisition price | 相手先である個人との守秘義務を有しており、Not disclosedとさせていただきます。 |
| Number of shares acquired | Acra Cut, Inc.: 100 株（議決権の数：100 個）；Intech, Inc.: 1,075 株（議決権の数：1,075 個） |
| Voting rights ownership percentage | Before Acra Cut, Inc. 0% / Intech, Inc. 0% → after Acra Cut, Inc. 100% / Intech, Inc. 100% |
| Impact on Business Performance | Acra Cut 社および Intech 社の新規連結に伴い、業績予想を上方修正 |
| Date of board resolution | 2026 年 3 月 5 日 |
| Contract Date | 2026 年 3 月 5 日 |
| Execution Date / Effective Date | 1 April 2026 (scheduled) |
| Valuation methodology | 第三者によるデューディリジェンス結果や当社による株式価値算定結果をふまえた合理性のある価額として決定 |
Items this document does not state (17)
Net Sales of the Subject CompanyOperating Profit of the Subject CompanyNet Income of the Subject CompanyNet Assets of the Subject CompanyExpenses other than the acquisition priceType of ConsiderationMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodFunding arrangementsGoodwill amountAmount of extraordinary income (loss)Independent valuation institutionSpecial CommitteeConditions Precedent to ExecutionManagement structure after acquisition
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.中期経営計画に沿って外科事業を拡大するため、Acra Cut社の脳神経外科用製品・ブランド・販路と、Intech社の製造能力・品質管理力を取得し、外科事業の成長および北米での現地製造拡大を目指すものです。現地製造の拡大により、米国政府の関税政策の影響を低減することも期待されています。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.